The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.
Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...
Hosted on MSN1d
FDA Approves TNKase To Treat Ischemic Strokes In AdultsIt is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, ...
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...
The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...
The approval is based on a study comparing TNKase to Activase in patients with acute ischemic stroke who presented with a disabling neurological deficit. Results show that TNKase was comparable to ...
The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...
The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results